

30 September 2014

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

AMENDMENT to July 2014 tender notification: in **bold** and strikethrough

1. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Docetaxel	Inj 20 mg; 1 vial	\$48.75	\$13.70	DBL Docetaxel (Hospira)	1%	1 October 2014	1 December 2014	Docetaxel Sandoz (Novartis)
Docetaxel	Inj 80 mg; 1 vial	\$195.00	\$29.99	DBL Docetaxel (Hospira)	1%	1 October 2014	1 December 2014	Docetaxel Sandoz (Novartis)

DBL Docetaxel will be listed in Section B of the Pharmaceutical Schedule (as PCT only – Specialist) from 1 October 2014 at the prices above. The price and subsidy of docetaxel (PCT ~~only – Retail Pharmacy~~ Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 October 2014.

The subsidy for docetaxel inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$2.63 per 1 mg to \$0.61 per 1 mg from ~~1 October 2014~~ **1 December 2014**.

2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

2. Tenders awarded to currently listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Bisoprolol fumarate	Tab 2.5 mg; 30 tablets, blister pack	\$3.88	\$2.40	Bosvate (Douglas)	1 January 2015	1 April 2015
Bisoprolol fumarate	Tab 5 mg; 30 tablets, blister pack	\$4.74	\$3.50	Bosvate (Douglas)	1 January 2015	1 April 2015
Bisoprolol fumarate	Tab 10 mg; 30 tablets, blister pack	\$9.18	\$6.40	Bosvate (Douglas)	1 January 2015	1 April 2015
Omeprazole	Cap 10 mg; 90 capsules, bottle	\$2.91	\$2.23	Omezol Relief (Mylan)	1 November 2014	1 February 2015
Omeprazole	Cap 20 mg; 90 capsules, bottle	\$3.78	\$2.91	Omezol Relief (Mylan)	1 November 2014	1 February 2015
Omeprazole	Cap 40 mg; 90 capsules, bottle	\$5.57	\$4.42	Omezol Relief (Mylan)	1 November 2014	1 February 2015

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Metronidazole	Inj 5 mg per ml; 100 ml bag	\$12.30	\$6.94	Metronidazole-AFT (AFT)	1%	1 February 2015	1 April 2015	Metronidazole Baxter (Baxter)

4. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Bisoprolol fumarate	Tab 2.5 mg; 30 tablets, blister pack	\$3.88	\$2.40	Bosvate (Douglas)	1%	1 January 2015	1 March 2015
Bisoprolol fumarate	Tab 5 mg; 30 tablets, blister pack	\$4.74	\$3.50	Bosvate (Douglas)	1%	1 January 2015	1 March 2015
Bisoprolol fumarate	Tab 10 mg; 30 tablets, blister pack	\$9.18	\$6.40	Bosvate (Douglas)	1%	1 January 2015	1 March 2015
Omeprazole	Cap 10 mg; 90 capsules, bottle	\$2.91	\$2.23	Omezol Relief (Mylan)	1%	1 November 2014	1 January 2015
Omeprazole	Cap 20 mg; 90 capsules, bottle	\$3.78	\$2.91	Omezol Relief (Mylan)	1%	1 November 2014	1 January 2015
Omeprazole	Cap 40 mg; 90 capsules, bottle	\$5.57	\$4.42	Omezol Relief (Mylan)	1%	1 November 2014	1 January 2015

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2012/13 Invitation to Tender, dated 31 October 2012 and 2013/14 Invitation to Tender, dated 07 November 2013:

2012/13 Invitation to Tender

Chemical Name	Line Item
Phenoxyethylpenicillin (Penicillin V)	Cap 250 mg
Phenoxyethylpenicillin (Penicillin V)	Cap 500 mg
Tranexamic Acid	Inj 100 mg per ml, 5 ml – 10 ml
Ziprasidone	Cap 20 mg

Chemical Name	Line Item
Ziprasidone	Cap 40 mg
Ziprasidone	Cap 60 mg
Ziprasidone	Cap 80 mg

2013/14 Invitation to Tender

Chemical Name	Line Item
Artesunate	Inj 60 mg
Celecoxib	Cap 100 mg
Celecoxib	Cap 200 mg
Cidofovir	Inj 75 mg per ml, 5 ml
Clofazimine	Cap 50 mg
Clonazepam	Tab 500 mcg
Clonazepam	Tab 2 mg
Cyclophosphamide	Inj 1 g
Cyclophosphamide	Inj 2 g
Cyclophosphamide	Tab 50 mg

Chemical Name	Line Item
Esomeprazole	Inj 40 mg
Etoricoxib	Tab 60 mg
Etoricoxib	Tab 90 mg
Etoricoxib	Tab 120 mg
Mebendazole	Tab 100 mg
Mefenamic acid	Cap 250 mg
Meloxicam	Tab 7.5 mg
Nitazoxanide	Oral liquid 100 mg per 5 ml
Spiramycin	Tab 500 mg
Tobramycin	Inj 40 mg per ml, 2 ml

For products included in the 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.